Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Equity Average (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Equity Average for 8 consecutive years, with $472.5 million as the latest value for Q4 2025.

  • Quarterly Equity Average changed N/A to $472.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $472.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $22.7 million for FY2019, 20.74% down from the prior year.
  • Equity Average for Q4 2025 was $472.5 million at Soleno Therapeutics, up from $367.5 million in the prior quarter.
  • The five-year high for Equity Average was $472.5 million in Q4 2025, with the low at $140.1 million in Q1 2025.